Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2023 Aug 15:2023.08.11.553000. [Version 1] doi: 10.1101/2023.08.11.553000

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Fig 3. — A) Dosing strategy of nivolumab and cabozantinib in both the phase 1b HCC neoadjuvant clinical trial and spQSP virtual clinical trial simulations. Nivolumab (240mg) is injected intravenously every 2 weeks for 8 weeks. Cabozantinib is administered orally every day for 8 weeks. B) Two-dimensional cross section of the spatial distribution of cells in the tumor compartment from a representative simulation at day 70 for both responders and non-responders. Simulation movies for three-dimensional cellular states over time are provided in Supplement Movies. C) Quantitative comparison of CD8+, CD3+, and Arg1+ Macrophage in the stratified patient groups (responder: n=19 vs. non-responder: n=40) at day 70. D) Longitudinal dynamics of average vascular density in the ABM sample of two groups of patients (R vs. NR). E) Cell composition in the ABM model outputs at day 70, grouped by treatment outcomes.